---
figid: PMC12066790__41392_2025_2197_Fig7_HTML
figtitle: Oncogenic mechanisms of EBV in nasopharyngeal carcinoma
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12066790
filename: 41392_2025_2197_Fig7_HTML.jpg
figlink: /pmc/articles/PMC12066790/figure/F7/
number: F7
caption: 'Oncogenic mechanisms of EBV in nasopharyngeal carcinoma. a Progression of
  NPC caused by EBV. b EBV induces genetic instability through inhibition of DNA repair,
  increased DNA methylation, chromosomal breaks at 11q23, and telomere elongation.
  c EBV promotes cell proliferation by activating NF-κB, Hedgehog, mTOR signaling
  pathways. d EBV accelerates G1/S progression in host cells by downregulating GSK3β
  expression, promoting degradation of p18, and activating the JAK2/STAT3 signaling
  pathway. e EBV infection promotes anti-apoptotic protein expression, inactivates
  pro-apoptotic proteins, reduces fumarate hydratase (FH) activity, and inhibits ferroptosis
  through the p62-Keap1-NRF2 pathway. f EBV evades immune surveillance by modulating
  PD-L1, MIC-A/B, and B7-H3 expression, and induces lactate, creatinine, and cytokine
  release, which recruits Treg cells and expands myeloid-derived suppressor cells
  (MDSCs), creating an immunosuppressive microenvironment. g EBV proteins promote
  cytokine/chemokine release, inhibit monocyte recruitment, induce TAM, and enhance
  mitochondrial activity via ROS suppression. h EBV-encoded proteins activate ANXA3-HIF-1α-VEGF
  and PI3K/AKT/mTOR/HIF-1α pathways to promote angiogenesis. i EBV stimulates glycolysis,
  increases glutamine uptake, and inhibits lipid degradation via the mTORC1/NF-κB
  and HIF-1α pathways. Red text: EBV components; Black text: host cell components;
  Direct oncogenesis: b–e; Indirect oncogenesis: f–i. This figure was created with
  BioRender.com'
papertitle: 'Viral oncogenesis in cancer: from mechanisms to therapeutics'
reftext: Qing Xiao, et al. Signal Transduct Target Ther. 2025;10(NA).
year: '2025'
doi: 10.1038/s41392-025-02197-9
journal_title: Signal Transduction and Targeted Therapy
journal_nlm_ta: Signal Transduct Target Ther
publisher_name: Nature Publishing Group
keywords: Tumour virus infections | Oncogenes
automl_pathway: 0.9403245
figid_alias: PMC12066790__F7
figtype: Figure
redirect_from: /figures/PMC12066790__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12066790__41392_2025_2197_Fig7_HTML.html
  '@type': Dataset
  description: 'Oncogenic mechanisms of EBV in nasopharyngeal carcinoma. a Progression
    of NPC caused by EBV. b EBV induces genetic instability through inhibition of
    DNA repair, increased DNA methylation, chromosomal breaks at 11q23, and telomere
    elongation. c EBV promotes cell proliferation by activating NF-κB, Hedgehog, mTOR
    signaling pathways. d EBV accelerates G1/S progression in host cells by downregulating
    GSK3β expression, promoting degradation of p18, and activating the JAK2/STAT3
    signaling pathway. e EBV infection promotes anti-apoptotic protein expression,
    inactivates pro-apoptotic proteins, reduces fumarate hydratase (FH) activity,
    and inhibits ferroptosis through the p62-Keap1-NRF2 pathway. f EBV evades immune
    surveillance by modulating PD-L1, MIC-A/B, and B7-H3 expression, and induces lactate,
    creatinine, and cytokine release, which recruits Treg cells and expands myeloid-derived
    suppressor cells (MDSCs), creating an immunosuppressive microenvironment. g EBV
    proteins promote cytokine/chemokine release, inhibit monocyte recruitment, induce
    TAM, and enhance mitochondrial activity via ROS suppression. h EBV-encoded proteins
    activate ANXA3-HIF-1α-VEGF and PI3K/AKT/mTOR/HIF-1α pathways to promote angiogenesis.
    i EBV stimulates glycolysis, increases glutamine uptake, and inhibits lipid degradation
    via the mTORC1/NF-κB and HIF-1α pathways. Red text: EBV components; Black text:
    host cell components; Direct oncogenesis: b–e; Indirect oncogenesis: f–i. This
    figure was created with BioRender.com'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ROS1
  - CDKN2A
  - TGFBR2
  - PDLIM7
  - MIR18A
  - PRKDC
  - MTOR
  - DHH
  - IHH
  - SHH
  - NFKB1
  - WRAP53
  - TAFAZZIN
  - WWTR1
  - H3P10
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - YAP1
  - MET
  - EGFR
  - AHR
  - NPC1
  - FH
  - CD274
  - CD276
  - KEAP1
  - GABPA
  - NFE2L2
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - IL1A
  - IL1B
  - IL6
  - MICA
  - CSF2
  - TNF
  - GPX4
  - MCL1
  - SLC7A11
  - BAD
  - FOXO3
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - STIM1
  - TAM
  - FGF2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - ANXA3
  - TGFB1
  - TGFB2
  - TGFB3
  - CCL22
  - CXCL8
  - PRKN
  - TNFAIP3
  - HIF1A
  - SMAD2
  - SMAD4
  - GSK3A
  - GSK3B
  - STAT3
  - JAK2
  - CDKN2C
  - UBE2I
  - MAFK
  - EEF1E1
  - ZNF197
  - ATRAID
  - LAMTOR1
  - TPPP2
  - H3P12
  - KLRK1
  - LDHA
  - SREBF1
  - HK2
  - KCNA5
  - KIF2A
  - KLK2
  - HOOK2
  - PNPLA2
  - GLUD1
  - GRID1
  - GLUD2
  - GRID2
  - FASTK
  - FOXD3-AS1
  - Methyl group
  - CRE
  - Lactate
  - TNF-a
  - ROS
  - Pyruvate
  - Citrate
  - TCA
  - carcinoma
  - cancer
---
